The CRUK Convergence Science Centre is a partnership between Imperial College London and The Institute of Cancer Research (ICR). We bring together researchers across these institutions from different disciplines to develop innovative ways to address challenges in cancer research and improve patient outcomes.
Five diverse projects were awarded funding from our 2025 Development Fund, selected by our Research Subcommittee for their innovation, potential patient impact, focus on convergence science, and use of cross-institutional expertise.
SPP1: A new drug target to stop the deadly spread of pancreatic cancer
A team of researchers at the ICR and Imperial College London, led by the Scientific Director of the CRUK Convergence Science Centre Prof Axel Behrens, have identified a new potential drug target to treat and stop the spread of pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and common types of pancreatic cancer.
Better Research Together: Why PPIE Matters in Cancer Research
When we work together through PPIE (Patient and Public Involvement and Engagement), cancer research becomes more relevant, inclusive, and impactful from Discovery to Clinical Research. Here we explore why PPIE matters, even in early-stage discovery research, the benefits for researchers and resources to help researchers get started.
